Media Room

For media inquiries, please contact:

Susan Willson
Vice President, Corporate Communications

Tel: 415-509-8202

swillson@stoketherapeutics.com

Media Downloads

Fact Sheet

TANGO Explainer

Fact Sheet

Dravet Syndrome

Photo

Ian F. Smith, Chief Executive Officer

Photo

Isabel Aznarez, Ph.D., Senior Vice President, Head of Research and Co-Founder

Illustration

TANGO-ASO

Logo

Stoke Therapeutics

Stoke In the News

Experts from Stoke are consulted for input to inform news coverage about our innovative science, the serious diseases we are working to address, and the industry we are proud to be a part of.

Learn More

Latest Press Releases

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

May 28, 2026

Read more

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

May 18, 2026

Read more

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

May 7, 2026

Read more

Learn more about our science

View all our publications and presentations

Featured Publications

Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome

Science Translational Medicine

August 26, 2020

Read Full Article

Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression

Nature Communications

July 9, 2020

Read Full Article

More About Stoke on Twitter